GSBS Dissertations and Theses

ORCID ID

0000-0002-8905-1589

Publication Date

2019-03-28

Document Type

Doctoral Dissertation

Academic Program

Interdisciplinary Graduate Program

Department

Gene Therapy Center; Neurology

First Thesis Advisor

Christian Mueller PhD

Second Thesis Advisor

Robert H. Brown DPhil, MD

Keywords

ALS, C9ORF72, Gene therapy for ALS, microRNAs, Epigenetics in ALS, C9ORF72 mouse model, Silencing of C9ORF72

Abstract

Amyotrophic lateral sclerosis (ALS) is a terminal neurodegenerative disease that affects motor neurons causing progressive muscle weakness and respiratory failure. In 2011, the presence of a hexanucleotide repeat expansion within chromosome 9 open reading frame 72(C9ORF72) was identified in ALS patient samples, becoming the major known genetic cause for ALS and frontotemporal dementia (FTD). Carriers of this mutation present reduced levels of C9ORF72 mRNA, RNA foci produced by the aggregating expansion and toxic dipeptides generated through repeat-associated non-ATG translation. These findings have led to multiple hypotheses on the pathogenesis of C9ORF72: 1) Haploinsufficiency, 2) RNA gain-of-function, 3) RAN Translation, and 4) Disrupted nucleocytoplasmic trafficking. Due to lack of treatments for this disease, we have pursued an AAV-RNAi dependent gene therapy approach, using an artificial microRNA (amiR) packaged in a recombinant adeno-associated virus (rAAV). After validating our in vitro results, we advanced to in vivo experiments using transgenic mice that recapitulate the major histopathological features seen in human ALS/FTD patients. Adult and neonate mice were injected through clinically relevant routes and our results indicate that AAV9-mediated amiR silencing not only reduced mRNA and protein levels of C9ORF72 but also the expansion derived toxic GP dipeptides. Although our amiR is not targeting the expansion itself but exon 3, we illustrate here that the evident dipeptide decrease is achievable due to the presence of aberrant transcripts in the cytoplasm containing miss-spliced Intron-HRE-C9ORF72 species. These encouraging results have led to the continued testing of this treatment as a therapeutic option for C9ORF72 - ALS patients.

DOI

10.13028/kw7m-9a26

Rights and Permissions

Copyright is held by the author, with all rights reserved.

Available for download on Monday, June 01, 2020

Share

COinS